For example, using pioglitazone (a drug in the thiazolidinedione class of peroxisome proliferator-activated receptor γ [PPAR-γ]—one of the most potent insulin-sensitizing drugs) to treat insulin-resistant non-diabetes patients who have a history of stroke reduced the risk of stroke, but increased the risk of bone fracture [14,15]. This evidence concerns the gene INS and diabetes mellitus.